ATE532785T1 - Als antikrebsmittel geeignete triazolopyrazinderivate - Google Patents

Als antikrebsmittel geeignete triazolopyrazinderivate

Info

Publication number
ATE532785T1
ATE532785T1 AT07734459T AT07734459T ATE532785T1 AT E532785 T1 ATE532785 T1 AT E532785T1 AT 07734459 T AT07734459 T AT 07734459T AT 07734459 T AT07734459 T AT 07734459T AT E532785 T1 ATE532785 T1 AT E532785T1
Authority
AT
Austria
Prior art keywords
derivatives used
cancer medicinal
triazolopyrazine derivatives
triazolopyrazine
medicinal
Prior art date
Application number
AT07734459T
Other languages
English (en)
Inventor
Hengmiao Cheng
Jingrong Jean Cui
Jacqui Elizabeth Hoffman
Lei Jia
Mary Catherine Johnson
Robert Kania
Phuong Thi Quy Le
Mitchell NAMBU
Mason Pairish
Hong Shen
Michelle Tran-Dube
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE532785T1 publication Critical patent/ATE532785T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT07734459T 2006-05-11 2007-04-30 Als antikrebsmittel geeignete triazolopyrazinderivate ATE532785T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79996606P 2006-05-11 2006-05-11
US89323107P 2007-03-06 2007-03-06
PCT/IB2007/001142 WO2007132308A1 (en) 2006-05-11 2007-04-30 Triazolopyrazine derivatives useful as anti-cancer agents

Publications (1)

Publication Number Publication Date
ATE532785T1 true ATE532785T1 (de) 2011-11-15

Family

ID=38441445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07734459T ATE532785T1 (de) 2006-05-11 2007-04-30 Als antikrebsmittel geeignete triazolopyrazinderivate

Country Status (32)

Country Link
US (2) US7732604B2 (de)
EP (1) EP2018383B1 (de)
JP (1) JP4377962B2 (de)
KR (1) KR101099161B1 (de)
CN (1) CN101443331A (de)
AP (1) AP2008004674A0 (de)
AR (1) AR060994A1 (de)
AT (1) ATE532785T1 (de)
AU (1) AU2007251283A1 (de)
BR (1) BRPI0711809A2 (de)
CA (1) CA2651363C (de)
CR (1) CR10383A (de)
EA (1) EA016204B1 (de)
EC (1) ECSP088871A (de)
ES (1) ES2376913T3 (de)
GE (1) GEP20115174B (de)
GT (1) GT200700039A (de)
HN (1) HN2007015177A (de)
IL (1) IL194813A0 (de)
MA (1) MA30411B1 (de)
ME (1) MEP36508A (de)
MX (1) MX2008014399A (de)
NL (1) NL2000613C2 (de)
NO (1) NO20085060L (de)
NZ (1) NZ572361A (de)
PE (1) PE20080067A1 (de)
RS (1) RS20080533A (de)
TN (1) TNSN08445A1 (de)
TW (1) TWI346115B (de)
UY (1) UY30334A1 (de)
WO (1) WO2007132308A1 (de)
ZA (1) ZA200809020B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) * 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
US20110039856A1 (en) * 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
PE20091468A1 (es) * 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
CN102014631A (zh) * 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
EP2298731A4 (de) * 2008-06-25 2011-09-21 Takeda Pharmaceutical Amidverbindung
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
WO2010059771A1 (en) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
JP2012511575A (ja) * 2008-12-12 2012-05-24 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのアザインドール誘導体
MX2011006682A (es) 2008-12-22 2011-07-13 Merck Patent Gmbh Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion.
PE20211639A1 (es) 2009-01-15 2021-08-24 Incyte Holdings Corp Procesos para preparar inhibidores de jak y compuestos intermediarios relacionado
DK2435443T3 (da) * 2009-05-28 2013-10-28 Vertex Pharma Aminopyrazoltriazolothiadiazolhæmmere af c-met-proteinkinase
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MX2012002179A (es) * 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
DE102009056886A1 (de) * 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
RS61281B1 (sr) * 2009-12-31 2021-02-26 Hutchison Medipharma Ltd Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
TWI423974B (zh) * 2010-02-11 2014-01-21 Hutchison Medipharma Ltd 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
EP3450432A1 (de) * 2010-05-17 2019-03-06 Incozen Therapeutics Pvt. Ltd. Neuartige 3,5-disubstituierte-3h-imidazo[4,5-b]pyridin- und 3,5- disubstituierte-3h-[1,2,3]triazol[4,5-b]pyridin-verbindungen als modulatoren der proteinkinase
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
EP2710003A1 (de) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Kondensierte bicyclische kinasehemmer
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
CN102516263B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102503959B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN103204844A (zh) 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
AP3908A (en) 2012-03-30 2016-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
MX2014011987A (es) 2012-04-03 2014-11-10 Novartis Ag Combinaciones de inhibidores de cinasa de tirosina y su uso.
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
CN105968115B (zh) * 2013-04-17 2018-11-09 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
AU2013402175B2 (en) * 2013-09-30 2017-09-07 Handok Inc. Novel triazolopyrazine derivative and use thereof
EP3229836B1 (de) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Menschliche monoklonale antikörper gegen axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
JP2018123059A (ja) * 2015-06-10 2018-08-09 石原産業株式会社 １−シクロプロピルエチルアミン又はその塩の製造方法
CN107922396B (zh) 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
WO2017049711A1 (zh) 2015-09-24 2017-03-30 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用
CN106928232B (zh) * 2015-12-31 2019-07-09 上海医药集团股份有限公司 喹啉类化合物及其盐的晶型、制备方法、组合物与应用
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
IL263429B (en) 2016-06-20 2022-08-01 Novartis Ag Crystalline forms of triazolopyrimidine compound
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
CN108276418A (zh) * 2018-03-20 2018-07-13 北京凯恩梅格医药科技有限公司 化合物、含有该化合物的药用组合物及其用途
US12258365B2 (en) * 2018-12-14 2025-03-25 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof
EP4267573A1 (de) 2020-12-23 2023-11-01 Genzyme Corporation Inhibitoren des deuterierten koloniestimulierenden faktor-1-rezeptors (csf-1r)
WO2025098425A1 (zh) * 2023-11-09 2025-05-15 浙江华海药业股份有限公司 趋化因子受体调节剂制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
JP2007516180A (ja) * 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
US9697529B2 (en) 2012-03-13 2017-07-04 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
AR060994A1 (es) 2008-07-30
HN2007015177A (es) 2010-06-09
NO20085060L (no) 2008-12-03
NL2000613C2 (nl) 2007-11-20
MX2008014399A (es) 2008-11-27
US20100105656A1 (en) 2010-04-29
ES2376913T3 (es) 2012-03-20
MA30411B1 (fr) 2009-05-04
WO2007132308A1 (en) 2007-11-22
CR10383A (es) 2008-11-11
IL194813A0 (en) 2009-08-03
TWI346115B (en) 2011-08-01
MEP36508A (en) 2011-02-10
TW200804384A (en) 2008-01-16
CA2651363A1 (en) 2007-11-22
CN101443331A (zh) 2009-05-27
US20070265272A1 (en) 2007-11-15
EA200870423A1 (ru) 2009-04-28
EP2018383B1 (de) 2011-11-09
CA2651363C (en) 2011-07-12
GEP20115174B (en) 2011-03-10
NZ572361A (en) 2012-02-24
GT200700039A (es) 2008-06-02
EP2018383A1 (de) 2009-01-28
ECSP088871A (es) 2008-12-30
TNSN08445A1 (fr) 2010-04-14
AP2008004674A0 (en) 2008-12-31
PE20080067A1 (es) 2008-03-10
EA016204B1 (ru) 2012-03-30
JP4377962B2 (ja) 2009-12-02
BRPI0711809A2 (pt) 2011-12-06
JP2009536636A (ja) 2009-10-15
AU2007251283A1 (en) 2007-11-22
KR20090006187A (ko) 2009-01-14
US7732604B2 (en) 2010-06-08
ZA200809020B (en) 2009-12-30
KR101099161B1 (ko) 2011-12-27
RS20080533A (sr) 2009-09-08
UY30334A1 (es) 2008-01-02

Similar Documents

Publication Publication Date Title
NO2021010I1 (no) telostritat ethyl
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
DK2041139T3 (da) Farmaceutiske forbindelser
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
DK1986650T3 (da) Manipulationssikre doserignsformer
DK2343071T3 (da) Farmaceutiske doseringsformer
ATE475662T1 (de) Dihydropyrazolopyrimidinonderivate
ATE483711T1 (de) Spiroindolinonderivate
EP1992348A4 (de) Pharmazeutische kombination
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
BRPI0715712A2 (pt) Composição farmacêutica
ATE460417T1 (de) Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
DK2035394T3 (da) 2-pyrazincarboxamidderivater
BRPI0719393A2 (pt) Composição farmacêutica
DK2035369T3 (da) Terapeutiske
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
DE602006016993D1 (de) Gleitelement
DK2086968T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater
DE502007002454D1 (de) Gleitelement
EP2197448A4 (de) Dosierplan
DE502007004416D1 (de) Avermectinderivate
ES1064279Y (es) Pañal calzoncillo
ES1064298Y (es) Pañal